Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2 Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer.

NCT01462214 is registered in ClinicalTrials.gov with Hans J. van der Vliet, MD, PhD as lead sponsor.

NCT NCT01462214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01462214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2 Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer.
Lead sponsor
Hans J. van der Vliet, MD, PhD
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2011
Completion date
January 31, 2017
Enrollment
96 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell cancer